Discovery of the metalloenzyme IsmB revises a pathway for coprostanol formation by the human gut microbiome

High levels of circulating cholesterol are associated with human cardiovascular diseases and an altered gut microbiome. Still, major gaps exist in our understanding of the interactions of cholesterol with gut microbes. The reductive transformation of cholesterol to the poorly absorbed sterol coprostanol by human gut bacteria has long been known, but the genetic and biochemical basis for this activity is only partially elucidated. Here, we discover and characterize a gut bacterial enzyme that catalyzes the reduction of cholestenone to coprostanone, the second step in the intestinal sterol metabolism (ism) pathway for coprostanol production. We identify a gene encoding a previously unknown 5{beta}-reductase, IsmB, a new member of the Fe-S cluster flavoenzyme superfamily, in the coprostanol producing organism Eubacterium coprostanoligenes. Biochemical characterization of IsmB confirms it is an anaerobic Fe-S cluster flavoenzyme and reveals specificity for reduction of an unanticipated intermediate, 5-cholesten-3-one, to coprostanone, revising the ism pathway. We also identify and characterize homologs of IsmB encoded in uncultured human gut bacteria that also encode the previously identified ism pathway enzyme IsmA, further supporting the role of IsmB in coprostanol formation. Finally, analysis of human stool metagenomics and metabolomics datasets further confirms the relevance of IsmB in the human gut microbiome, and analyses of human serum metabolomics from Framingham Heart Study participants reveal negative correlation between serum cholesterol levels and the presence of IsmA/IsmB encoders in the gut. Together, these results show the utility of combining biochemistry and stool metagenomic analysis for gut microbial enzyme discovery, and suggests IsmA/IsmB-encoding gut bacteria carry potential benefits for cholesterol homeostasis and cardiovascular health.